Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Bergur V. Stefánsson"'
Autor:
Michele Provenzano, Niels Jongs, Priya Vart, Bergur V. Stefánsson, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Publikováno v:
Kidney International Reports, Vol 7, Iss 3, Pp 436-443 (2022)
Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease (CKD). We performed an analysis of the Dapagliflozin and Prevention of Adv
Externí odkaz:
https://doaj.org/article/1ea3200adb9746dca4e6abb643d67f2e
Autor:
Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie Cain, Ricardo Correa-Rotter
Publikováno v:
Data in Brief, Vol 37, Iss , Pp 107237- (2021)
Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuri
Externí odkaz:
https://doaj.org/article/3e19504c357c42f6a45de1161b69b186
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure
Autor:
Lars Køber, David C. Wheeler, Peter Rossing, Pardeep S. Jhund, Investigators, F Martinez, Hiddo J.L. Heerspink, Dapa-Hf Trial Committees, Niels Jongs, Fan Fan Hou, Mikaela Sjöstrand, Robert D. Toto, Ricardo Correa-Rotter, Marc S. Sabatine, Dapa-Ckd, Cecilia Karlsson, Magnus Lindberg, Kieran F. Docherty, Priya Vart, John J.V. McMurray, David L. DeMets, Anna Maria Langkilde, Silvio E. Inzucchi, Glenn M. Chertow, Scott D. Solomon, Mikhail Kosiborod, Olof Bengtsson, Bergur V. Stefánsson, Piotr Ponikowski
Publikováno v:
Lancet Diabetes & Endocrinology, 24-34. ELSEVIER SCIENCE INC
STARTPAGE=24;ENDPAGE=34;ISSN=2213-8587;TITLE=Lancet Diabetes & Endocrinology
STARTPAGE=24;ENDPAGE=34;ISSN=2213-8587;TITLE=Lancet Diabetes & Endocrinology
BACKGROUND: Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the D
Autor:
Michał Nowicki, Bergur V. Stefánsson, C. David Sjöström, Fan Fan Hou, Dapa-Ckd Trial Committees, Niels Jongs, John J.V. McMurray, Peter Rossing, Ricardo Correa-Rotter, Glenn M. Chertow, Robert D. Toto, Investigators, David C. Wheeler, István Wittmann, Hiddo J.L. Heerspink, Anna Maria Langkilde, Tom Greene
Publikováno v:
Wheeler, D C, Jongs, N, Stefansson, B, Chertow, G M, Greene, T, Hou, F F, Langkilde, A M, McMurray, J J, Rossing, P, Nowicki, M, Wittmann, I, Correa-Rotter, R, Sjostrom, C D, Toto, R D, Heerspink, H J L & DAPA-CKD Trial Comm Investigators 2022, ' Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis : a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial ', Nephrology Dialysis Transplantation, vol. 37, no. 9, pp. 1647–1656 . https://doi.org/10.1093/ndt/gfab335
Background Despite renin–angiotensin–aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. The objective of this prespecified analysis of the dapagliflozin and p
Autor:
Dapa-Ckd Trial Committees, David C. Wheeler, John J.V. McMurray, C. David Sjöström, Peter Rossing, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Hiddo J.L. Heerspink, Robert D. Toto, Ricardo Correa-Rotter, Investigators, Bergur V. Stefánsson, Tom Greene
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 743-754. ELSEVIER SCIENCE INC
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change
Autor:
John J.V. McMurray, Niels Jongs, Scott D. Solomon, C. David Sjöström, Ricardo Correa-Rotter, Investigators, Douwe Postmus, Glenn M. Chertow, Peter Rossing, Robert D. Toto, Bergur V. Stefánsson, Fan Fan Hou, Dapa-Ckd Trial Committees, Hiddo J.L. Heerspink, David C. Wheeler, Anna Maria Langkilde
Publikováno v:
JACC. Heart failure, 9(11), 807-820. ELSEVIER SCI LTD
McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
OBJECTIVES: The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF).BACKGROUND: Patients with CKD, with and without type 2 diabetes, were enrolled in the
Autor:
Niels Jongs, Anna Maria Langkilde, John J.V. McMurray, Robert D. Toto, Fan Fan Hou, Ricardo Correa-Rotter, Bergur V. Stefánsson, Priya Vart, Hiddo J.L. Heerspink, David Wheeler, José Luis Górriz, Glenn M. Chertow, C. David Sjöström, Peter Rossing
Publikováno v:
Journal of the American Society of Nephrology, 32(8), 2352-2361. AMER SOC NEPHROLOGY
Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167
J Am Soc Nephrol
Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167
J Am Soc Nephrol
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and
Autor:
Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, David C. Wheeler, Claes Held, Tom Greene, Hiddo J.L. Heerspink, R D Toto, Anna Maria Langkilde, Johannes F.E. Mann, Fan Fan Hou, Investigators, Peter Rossing, C. David Sjöström, Glenn M. Chertow, John J.V. McMurray, Bergur V. Stefánsson
Publikováno v:
Circulation, 143(5), 438-448. LIPPINCOTT WILLIAMS & WILKINS
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event,
Autor:
Niels, Jongs, Glenn M, Chertow, Tom, Greene, John J V, McMurray, Anna Maria, Langkilde, Ricardo, Correa-Rotter, Naoki, Kashihara, Peter, Rossing, C David, Sjöström, Bergur V, Stefánsson, Robert D, Toto, David C, Wheeler, Hiddo J L, Heerspink
Publikováno v:
Journal of the American Society of Nephrology. AMER SOC NEPHROLOGY
Dapagliflozin reduces kidney failure risk in patients with CKD but can result in a reversible acute reduction in eGFR upon treatment initiation. Determinants of this eGFR reduction and its associations with efficacy and safety outcomes are unknown.Th
Autor:
Niels Jongs, Bergur V. Stefánsson, Ricardo Correa-Rotter, Robert D. Toto, John J.V. McMurray, Tom Greene, Dapa-Ckd Trial Committees, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Investigators, Peter Rossing
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 755-766. ELSEVIER SCIENCE INC
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89091bdd4249d265893bbdc171c8e7e
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272